Analysts Offer Predictions for Marinus Pharmaceuticals Inc’s Q3 2019 Earnings (MRNS)

Share on StockTwits

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) – Investment analysts at Svb Leerink issued their Q3 2019 earnings estimates for shares of Marinus Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 12th. Svb Leerink analyst M. Goodman forecasts that the biopharmaceutical company will post earnings of $0.15 per share for the quarter. Svb Leerink has a “Outperform” rating on the stock. Svb Leerink also issued estimates for Marinus Pharmaceuticals’ FY2019 earnings at ($0.55) EPS.

MRNS has been the subject of a number of other reports. Cantor Fitzgerald set a $22.00 target price on shares of Marinus Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, December 26th. Mizuho reiterated a “buy” rating and issued a $13.00 target price on shares of Marinus Pharmaceuticals in a research note on Tuesday, December 11th. LADENBURG THALM/SH SH set a $22.00 target price on shares of Marinus Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 11th. Zacks Investment Research cut shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, February 27th. Finally, Jefferies Financial Group assumed coverage on shares of Marinus Pharmaceuticals in a research note on Tuesday, March 5th. They issued a “buy” rating and a $10.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Marinus Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $14.63.

NASDAQ MRNS opened at $3.79 on Friday. The company has a market capitalization of $151.18 million, a price-to-earnings ratio of -4.21 and a beta of 3.20. Marinus Pharmaceuticals has a 12-month low of $2.36 and a 12-month high of $10.54.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.02.

In other news, CEO Christopher Michael Cashman sold 8,142 shares of the business’s stock in a transaction on Monday, January 28th. The shares were sold at an average price of $3.13, for a total value of $25,484.46. Following the completion of the sale, the chief executive officer now directly owns 239,761 shares in the company, valued at $750,451.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.60% of the stock is currently owned by insiders.

Several institutional investors have recently modified their holdings of the company. Meeder Asset Management Inc. lifted its stake in shares of Marinus Pharmaceuticals by 1,082.4% in the fourth quarter. Meeder Asset Management Inc. now owns 10,819 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 9,904 shares during the last quarter. Partner Investment Management L.P. acquired a new stake in shares of Marinus Pharmaceuticals in the third quarter worth $112,000. Wells Fargo & Company MN lifted its stake in shares of Marinus Pharmaceuticals by 298.3% in the third quarter. Wells Fargo & Company MN now owns 17,755 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 13,297 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Marinus Pharmaceuticals by 48.9% in the fourth quarter. Rhumbline Advisers now owns 48,163 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 15,815 shares during the last quarter. Finally, Gabelli Funds LLC acquired a new stake in shares of Marinus Pharmaceuticals in the fourth quarter worth $49,000. Institutional investors and hedge funds own 84.65% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.

Featured Story: Discover Your Risk Tolerance

Earnings History and Estimates for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.